Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customersâ research, therapeutic and vaccine programs. This segmentâs business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segmentâs business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.
BörsenkĂŒrzelMRVI
Name des UnternehmensMaravai LifeSciences Holdings Inc
IPO-datumNov 20, 2020
CEOBrust (Bernd)
Anzahl der mitarbeiter570
WertpapierartOrdinary Share
GeschÀftsjahresendeNov 20
Addresse10770 Wateridge Circle Suite 200
StadtSAN DIEGO
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92121
Telefon18585460004
Websitehttps://www.maravai.com/
BörsenkĂŒrzelMRVI
IPO-datumNov 20, 2020
CEOBrust (Bernd)